6-(吡啶-3-基)吡嗪-3(2H)-酮 | 78784-65-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 6-(吡啶-3-基)吡嗪-3(2H)-酮
• 英文名称: 6-(pyridin-3-yl)pyridazin-3(2H)-one
• 英文别名: 6-(pyridin-3-yl)pyridazin-3(2H)one；6-pyridin-3-yl-2H-pyridazin-3-one；6-(3-Pyridyl)-3(2H)-pyridazinone；3-pyridin-3-yl-1H-pyridazin-6-one
• CAS: 78784-65-3
• 化学式: C₉H₇N₃O
• 分子量: 173.174
• InChiKey: OQYCHIKONQFIQO-UHFFFAOYSA-N

物化性质

• 密度：
  1.31±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-(吡啶-3-基)吡嗪-3(2H)-酮 在 吡啶 、 tetraphosphorus decasulfide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-((2-Methylbenzyl)thio)-6-(pyridin-3-yl)pyridazine
  参考文献：
  名称：

  Structure–activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators

  摘要：

  Excitatory amino acid transporter 2 (EAAT2) is the major glutamate transporter and functions to remove glutamate from synapses. A thiopyridazine derivative has been found to increase EAAT2 protein levels in astrocytes. A structure-activity relationship study revealed that several components of the molecule were required for activity, such as the thioether and pyridazine. Modification of the benzylthioether resulted in several derivatives (7-13, 7-15 and 7-17) that enhanced EAAT2 levels by >6-fold at concentrations <5 mu M after 24 h. In addition, one of the derivatives (7-22) enhanced EAAT2 levels 3.5-3.9-fold after 24 h with an EC50 of 0.5 mu M. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.009
• 作为产物：
  描述：

  3-乙酰基吡啶 在 potassium carbonate 、 肼 作用下， 以 水 为溶剂， 生成 6-(吡啶-3-基)吡嗪-3(2H)-酮
  参考文献：
  名称：

  具有血栓烷A2合成酶抑制和支气管扩张双重活性的新型抗哮喘药。IV。2- [2-（1-咪唑基）乙基] -4-（3-吡啶基）-1（2H）-酞嗪酮。

  摘要：

  描述了几种与2- [2-（1-咪唑基）乙基] -4-（3-吡啶基）-1（2H）-酞嗪酮有关的化合物的合成和药理学评价。发现酞嗪酮骨架的苯基部分在血栓烷A2合成酶抑制和支气管扩张活性中均起重要作用。此外，显示了在4-位的3-吡啶基对于体内血栓烷A2合成酶抑制活性是必需的。

  DOI：

  10.1248/cpb.42.1850

文献信息

• 6- And 8-heteroaryl-1,2,4-triazolo[4,3-b]pyridazines
  申请人：American Cyanamid Company

  公开号：US04260756A1

  公开（公告）日：1981-04-07

  This disclosure describes novel 6- and 8-heteroaryl and substituted 6- and 8-heteroaryl-1,2,4-triazolo[4,3-b]-pyridazines and their use as agents for treating anxiety.

  这份披露描述了新颖的6-和8-杂芳基及取代的6-和8-杂芳基-1,2,4-三唑并[4,3-b]-吡啶嗪，以及它们作为治疗焦虑症的药剂的用途。
• Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV
  作者：Kenji Namoto、Finton Sirockin、Nils Ostermann、Francois Gessier、Stefanie Flohr、Richard Sedrani、Bernd Gerhartz、Jörg Trappe、Ulrich Hassiepen、Alokesh Duttaroy、Suzie Ferreira、Jon M. Sutton、David E. Clark、Garry Fenton、Mandy Beswick、Daniel K. Baeschlin

  DOI：10.1016/j.bmcl.2013.12.118

  日期：2014.2

  The successful launches of dipeptidyl peptidase IV (DPP IV) inhibitors as oral anti-diabetics warrant and spur the further quest for additional chemical entities in this promising class of therapeutics. Numerous pharmaceutical companies have pursued their proprietary candidates towards the clinic, resulting in a large body of published chemical structures associated with DPP IV. Herein, we report the

  作为口服抗糖尿病药，成功推出了二肽基肽酶IV（DPP IV）抑制剂，并刺激了这一有前途的治疗方法中对其他化学实体的进一步追求。许多制药公司已经将他们的专利候选人推向诊所，从而导致大量已公布的与DPP IV相关的化学结构。在本文中，我们报道了基于C-（1-芳基-环己基）-甲胺支架的新型DPP IV抑制化学型的发现，以及对低nM效价选择性抑制DPP IV并表现出优异的口服药代动力学的化合物的优化在大鼠中的轮廓。
• One-Pot Preparation of 6-Substituted 3(2<i>H</i>)-Pyridazinones from Ketones
  作者：W. J. Coates、A. Mckillop

  DOI：10.1055/s-1993-25861

  日期：——

  A one-pot process for the preparation of 6-phenyl-3(2H)-pyridazinone from acetophenone and glyoxylic acid has been investigated and shown to have wide utility in the preparation of 6- and 5,6-substituted 3(2H)-pyridazinones. Limitations to the process encountered with 2′-hydroxyacetophenone and with basic heteroaromatic ketones have been overcome, and the processes described offer the rapid and efficient synthesis of many 6-substituted pyridazinones from readily available ketones.

  一种利用乙酰苯和乙醛酸制备6-苯基-3(2H)-吡哒嗪酮的一锅法工艺已被研究，并证明在制备6-和5,6-取代的3(2H)-吡哒嗪酮方面具有广泛应用。该工艺解决了遇到2′-羟基乙酰苯和基本杂芳香酮时的局限性问题，并提供了一种快速高效合成多种6-取代吡哒嗪酮的方法，原料为易得的酮类。
• [EN] PYRIDAZINONE-AMIDES DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIDAZINONE-AMIDES
  申请人：MERCK PATENT GMBH

  公开号：WO2014121931A1

  公开（公告）日：2014-08-14

  The present invention relates to compounds of formula (I) wherein R1, Ra, Rb and Z have the meaning given in claim 1, and their use in the prophylaxis and treatment of diseases.

  本发明涉及式（I）的化合物，其中R1、Ra、Rb和Z具有权利要求1中给出的含义，并且它们在预防和治疗疾病中的用途。
• Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors
  作者：Eun-Young Kim、Seung-Tae Kang、Heejung Jung、Chi Hoon Park、Chang-Soo Yun、Jong Yeon Hwang、Byung Jin Byun、Chong Ock Lee、Hyoung Rae Kim、Jae Du Ha、Do Hyun Ryu、Sung Yun Cho

  DOI：10.1007/s12272-015-0703-7

  日期：2016.4

  A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.

  合成了一系列取代有吗啉-嘧啶衍生物的吡嗪-3-酮，并评估其作为c-Met酶的酪氨酸激酶抑制剂以及对Hs746T人胃癌细胞系的抗增殖活性。大多数化合物表现出良好的生物活性，其中化合物10、12a和14a展现了优异的c-Met酶抑制活性和Hs746T细胞基础活性。